MedTrace Logo

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2026-02-09

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Conditions

Interventions

DRUG

IDE-161

Oral Medication

DRUG

Pembrolizumab

Intravenous Infusion

Sponsors & Collaborators

Principal Investigators

  • Darrin Beaupre, MD,PhD · IDEAYA Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-18
Primary Completion
2026-10-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05787587 on ClinicalTrials.gov